JSJulia Szlążek

Julia Szlążek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Szlążek has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Atypical hemolytic- uremic syndrome (aHUS) – a rare disease, new hopes in treatment. Review

    by Marta Turek, Julia Szlążek, Michalina Zagalska, Kamil Kerknawi, Adam Jan Ząbek, Adam Grzebinoga, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Barbara Roguska, Tomasz Tamborski

    Atypical hemolytic uremic syndrome (aHUS) is a rare disease stemming from complement system dysregulation, manifesting as thrombotic microangiopathy (TMA). It is also described as a heritable, life-threatening disorder characterized by uncontrolled complement activation, leading to systemic TMA and damage to vital organs. aHUS is frequently considered a prototypical form of complement-mediated TMA (CM-TMA), resulting from the dysregulation and overactivation of the alternative complement pathway, culminating in excessive terminal complement activation. The classical clinical triad of aHUS encompasses thrombocytopenia, microangiopathic hemolytic anemia and acute kidney injury.This review paper aims to provide a comprehensive overview of atypical hemolytic uremic syndrome (aHUS). Specifically, this work intends to define aHUS, encompassing its pathomechanism, clinical presentation, and diagnostic criteria. Attention is also directed towards secondary aHUS, which can occur in association with various underlying conditions. Furthermore, this review covers current, available treatment modalities utilizing eculizumab and ravulizumab, providing a comparative analysis of these two agents and highlighting their significance as terminal complement pathway inhibitors. The fundamental mechanism underlying aHUS is the uncontrolled activation of the complement system, particularly its alternative pathway, leading to systemic TMA and life-threatening organ damage. The management of aHUS has been transformed with the introduction of terminal complement inhibitors, such as eculizumab and ravulizumab, which have demonstrated efficacy in improving hematological and renal parameters. Ravulizumab, a long-acting C5 inhibitor, allows for less frequent dosing compared to eculizumab. This paper underscores the importance of early recognition and the implementation of complement inhibitor therapy in aHUS and indicates the necessity for future comparative studies of eculizumab and ravulizumab to optimize treatment strategies.


  • Open Access

    CHANGING THE TRAJECTORY OF GROWTH: THE APPLICATION OF VOSORITIDE IN CHILDREN WITH ACHONDROPLASIA. A CHANCE FOR IMPROVED QUALITY OF LIFE?

    by Marta Turek, Julia Szlążek, Michalina Zagalska, Adam Jan Ząbek, Kamil Kerknawi, Paulina Mikulec, Marceli Mesyasz, Tomasz Tamborski, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska

    Achondroplasia (ACH) is the most common skeletal dysplasia and the leading genetic cause of dwarfism. It is characterized by disproportionate short stature and lifelong medical complications, with an estimated incidence of 1 in 25,000–30,000 live births. The condition results from a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, causing receptor overactivation and impaired bone growth at the growth plates. This review provides an overview of achondroplasia, including its pathophysiology, clinical features, diagnostic methods, and novel therapeutic options, with emphasis on vosoritide. Historically, management has focused on symptomatic treatment and surgical interventions to address complications such as foramen magnum stenosis, hydrocephalus, and postural deformities. Vosoritide (Voxzogo) marks a breakthrough as the first disease-modifying therapy targeting the underlying pathophysiology. It is a C-type natriuretic peptide (CNP) analog that inhibits the overactive MAPK pathway, thereby promoting chondrocyte proliferation and differentiation in growth plates and enabling endochondral bone growth. Phase 3 clinical trials demonstrated that vosoritide significantly increases annual growth velocity (by approximately 1.57 cm) and improves body proportions, with a favorable safety profile. Reported adverse effects were generally mild, including transient hypotension and injection site reactions. Despite these advances, vosoritide therapy does not eliminate the need for coordinated multidisciplinary care and psychological support. Patients require ongoing monitoring and management of associated complications, including neurological, orthopedic, respiratory, and developmental issues. In summary, achondroplasia remains the most frequent genetic form of dwarfism, traditionally managed through supportive care and surgery. The introduction of vosoritide represents a paradigm shift, offering the first targeted therapy that directly modifies disease progression and opens new perspectives for improving patients’ quality of life.

  • Air trapping - exercise-induced asthma (EIA): pathomechanism, diagnosis and novel prevention strategies

    by Julia Szlążek, Marta Turek, Michalina Zagalska, Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska

    Background: Exercise-induced asthma (EIA), also known as exercise-induced bronchoconstriction (EIB), is characterized by transient airway narrowing triggered by physical exertion, leading to symptoms such as cough, wheezing, shortness of breath, and chest tightness. The pathophysiology of EIA involves osmotic and thermal mechanisms, resulting in the release of inflammatory mediators that induce bronchospasm.Aim of the study: This systematic review aims to elucidate the pathomechanisms, diagnostic approaches, and treatment modalities for EIA.Material and methods: The review follows PRISMA guidelines and includes 31 studies from PubMed and ClinicalTrials.gov, focusing on adults reporting EIA symptoms. Diagnostic methods primarily include spirometry pre- and post-exercise, with a ≥10% decrease in FEV1 indicating EIA. Provocation tests, such as eucapnic voluntary hyperventilation (EVH), and novel methods like diaphragm electromyography (EMGdi), are also explored.Results: Management strategies encompass pharmacological treatments, including short-acting beta-2 agonists (SABAs), inhaled corticosteroids (ICS), and leukotriene receptor antagonists (LTRAs), alongside non-pharmacological approaches like warm-up exercises and breathing retraining, which have been reviewed as parts of phase 3 and phase 4 clinical trials. The consistent use of standardised exercise challenge tests and FEV1 measurements, along with robust study designs, strengthens the evidence for prevention method efficacy.Conclusions: The review highlights the need for standardized diagnostic criteria and personalised treatment plans to improve patient outcomes and quality of life.

  • Open Access

    The Impact of Physical Activity on the Course of Inflammatory Bowel Diseases

    by Adam Grzebinoga, Julia Szlążek, Michalina Zagalska, Marta Turek, Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Barbara Roguska, Tomasz Tamborski

    Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated conditions with increasing global prevalence. While the etiology of IBD is multifactorial—encompassing genetic, environmental, microbial, and immunological components—emerging evidence highlights the role of lifestyle factors, such as physical activity (PA), in modulating disease mechanisms and outcomes. This review explores the multifaceted impact of PA on IBD, focusing on gut microbiota composition, intestinal barrier integrity, and immune function. Moderate, regular exercise has been shown to beneficially influence gut microbial diversity, promote the production of anti-inflammatory metabolites, and support mucosal barrier function. Additionally, PA modulates systemic and intestinal immune responses, potentially reducing pro-inflammatory cytokine activity. In CD, visceral adiposity and adipokine dysregulation further complicate disease progression, suggesting a specific relevance of PA in this patient group. While observational and interventional studies indicate that PA may reduce anxiety and improve quality of life in IBD patients, the evidence regarding its effects on somatic symptoms and disease course remains inconclusive. Future randomized controlled trials are essential to establish standardized exercise protocols and clarify the therapeutic potential of PA in IBD management. Nonetheless, current data support PA as a safe, promising adjunct to conventional therapies, with potential benefits for both physical and psychological health in IBD patients.

  • Open Access

    Nanotechnology in the Treatment of Glioblastoma Multiforme: Enhancing Radiotherapy and Chemotherapy with Nanoparticles

    by Emilia Gabriela Chrzanowska, Jakub Paweł Kuźniar, Julia Szlążek, Adam Jan Ząbek, Michalina Zagalska, Marta Turek, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska, Michał Kuźniar

    Introduction: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, associated with poor prognosis despite standard treatment modalities including surgery, radiotherapy, and chemotherapy. The limited efficacy of these therapies is due, in part, to the difficulty of complete tumor resection, the blood-brain barrier (BBB) hindering drug penetration, and the tumor’s resistance mechanisms to chemotherapy and radiotherapy. Nanoparticles (NPs) offer promising solutions for targeted drug delivery, potentially improving therapeutic outcomes. This review summarizes recent advances in nanoparticle-based therapies for GBM. Methods: A literature review was conducted by analyzing 38 scientific articles using PubMed and Google Scholar databases. Studies published within the last five years focusing on the application of nanoparticles in GBM treatment were included. Various types of nanoparticles, their mechanisms of action, and the potential benefits and limitations of their clinical use were discussed. Results: The literature indicates that nanoparticles enhance drug permeability across the BBB, improve tumor penetration, and increase treatment efficacy. Their use in GBM therapy enables more precise drug delivery, reduces systemic toxicity, and minimizes damage to healthy tissues. Furthermore, nanoparticles play a significant role in combination therapies, potentially leading to a synergistic therapeutic effect. Conclusions: Nanoparticles represent a novel and promising strategy for the treatment of GBM, offering targeted drug delivery and improved therapeutic outcomes. However, further research is needed to optimize nanoparticle formulations and to evaluate their long-term safety and efficacy in clinical settings.

  • Open Access

    Innovative Approaches in the Treatment of Pancreatic Cancer: The Role of CAR T-Cell Therapy

    by Jakub Kuźniar, Emilia Gabriela Chrzanowska, Julia Szlążek, Adam Jan Ząbek, Michalina Zagalska, Marta Turek, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska, Anna Katarzyna Kuźniar

    IntroductionPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal gastrointestinal cancers, marked by late diagnosis, rapid progression, and resistance to treatment, resulting in a five-year survival rate below 10%. Chimeric antigen receptor T-cell (CAR T-cell) therapy has shown success in hematologic malignancies, sparking interest in its potential for solid tumors like PDAC. This paper reviews current knowledge on CAR T-cell therapy in PDAC, focusing on challenges, future prospects, and available studies. MethodologyThis literature review is based on a search of PubMed and Google Scholar for publications from the last 10 years. Fifty sources, including original studies, reviews, and clinical reports, were analyzed with focus on mechanisms of action, preclinical/clinical outcomes, safety, and toxicity. ResultsStudies show that CAR T-cell therapy can stabilize PDAC and even induce remission when targeting tumor-specific antigens. However, major obstacles remain: poor tumor penetration, toxicity (e.g., cytokine release syndrome), and "on-target, off-tumor" effects. Clinical trials report modest CAR T-cell expansion and persistence, suggesting the need for improved design and strategies. ConclusionsWhile CAR T-cell therapy for PDAC is promising, its effectiveness is hindered by the tumor microenvironment and side effects. Future directions include better antigen targeting, modified CAR constructs, combination therapies, and personalized or allogeneic CAR T-cell approaches to enhance outcomes in this difficult-to-treat cancer.

  • Open Access

    The Evolution of Methotrexate Applications: A Multidimensional Approach to Treating Various Disorders – A Literature Review

    by Tomasz Tamborski, Michalina Zagalska, Adam Jan Ząbek, Jakub Paweł Kuźniar, Marta Turek, Adam Grzebinoga, Julia Szlążek, Barbara Roguska, Magdalena Szostak, Emilia Gabriela Chrzanowska

    IntroductionMethotrexate (MTX) is a key cytostatic and immunosuppressive drug widely used in oncology and autoimmune disease treatment. It acts as a folic acid antagonist, inhibiting DNA synthesis and cell division. This review explores new applications of MTX beyond its traditional role. MTX shows potential in treating neuromyelitis optica spectrum disorders (NMOSD) as an alternative when other immunosuppressants are ineffective. In ophthalmic diseases like non-infectious uveitis and scleritis, it reduces inflammation and corticosteroid dependence. MTX is also used for unruptured ectopic pregnancy as a non-surgical option in select cases, with meta-analyses confirming its effectiveness, though resolution times may vary. Additionally, emerging evidence suggests MTX may help prevent cardiovascular diseases in patients with inflammatory conditions by improving atherosclerosis biomarkers. ObjectiveThis review aims to provide an overview of MTX’s expanding applications, pharmacological properties, and the importance of therapy monitoring. Current State of KnowledgeMTX is well-established in both low doses for autoimmune diseases like rheumatoid arthritis and high doses for chemotherapy. While effective, it has significant toxicity risks, particularly at high doses, necessitating therapeutic drug monitoring (TDM) to minimize adverse effects like nephrotoxicity and mucositis. MethodsThis review synthesizes data from review articles, original studies, meta-analyses, and clinical guidelines, covering MTX’s mechanisms, pharmacokinetics, clinical applications, toxicity management, and TDM role. ConclusionsMTX remains a cornerstone in disease treatment due to its broad pharmacological spectrum. Effective therapy requires proper dosing, toxicity management, and monitoring strategies. Ongoing research seeks to optimize MTX use while minimizing risks.


  • Open Access

    Thalidomide - a chance for use in modern disease treatment?

    by Marta Turek, Julia Szlążek, Michalina Zagalska, Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Tomasz Tamborski, Adam Grzebinoga, Barbara Roguska

    Thalidomide, despite its controversial history associated with teratogenic effects is currently used in the treatment of various conditions including oncological, immunological and dermatological diseases. The drug exhibits anti-inflammatory, immunomodulatory and anti-angiogenic effects, making it potentially effective in the treatment of various diseases. The mechanism of action is based on modulating the CRL4CRBN E3 ubiquitin ligase complex by binding to cereblon (CRBN), which leads to a change in the substrates recognized by this complex and the degradation of specific proteins. Thalidomide is used in the treatment of multiple myeloma, especially in cases resistant to other treatment methods. In addition, it can support the treatment of glioblastoma multiforme due to its anti-angiogenic and immunomodulatory effects. It is also used in the treatment of Crohn's disease, systemic lupus erythematosus, and idiopathic pulmonary fibrosis (IPF). In Crohn's disease it works by blocking TNF-α and modulating the immune response. In cutaneous lupus erythematosus it reduces inflammation, modulates the immune response and inhibits angiogenesis. In IPF, it inhibits the production of pro-inflammatory cytokines and reduces oxidative stress. The use of thalidomide is associated with a risk of teratogenicity, which requires strict control and the use of effective methods of contraception. In addition thalidomide can cause side effects, mainly hematological and gastrointestinal disorders. Due to the side effect profile, the use of thalidomide requires caution and close monitoring of the patient by a physician.


  • Open Access

    Athletic Pubalgia – A Significant Diagnostic and Therapeutic Challenge in Athletes?

    by Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Michalina Zagalska, Marta Turek, Tomasz Tamborski, Adam Grzebinoga, Julia Szlążek, Barbara Roguska, Karolina Maria Mitręga

    Introduction: Athletic pubalgia is a clinical syndrome involving overuse injuries of the musculo-tendinous structures around the pubic symphysis. It primarily affects athletes engaged in sports requiring rapid directional changes, kicking, and high core and lower limb load. This study aims to present the current understanding of the pathophysiology, epidemiology, clinical presentation, and treatment strategies of athletic pubalgia. Methods: A review of 25 scientific publications from PubMed and Google Scholar was conducted. The analysis focused on risk factors, clinical symptoms, diagnostic approaches, and both conservative and surgical management strategies in athletes. Results: Athletic pubalgia predominantly affects male athletes in soccer, hockey, and American football. Symptoms include exertional groin pain. Diagnosis is based on clinical assessment, functional testing, and imaging—especially MRI. Conservative treatment involving physiotherapy and postural re-education is effective in most cases. Refractory cases may require surgical intervention such as posterior inguinal wall repair or adductor tenotomy. Conclusions: Athletic pubalgia presents a significant diagnostic and therapeutic challenge. Effective management requires an interdisciplinary and individualized approach. Further clinical studies are needed to develop standardized diagnostic and therapeutic algorithms.


  • Open Access

    Hydroxychloroquine – Beyond Malaria: Its Role in Rheumatology and COVID-19 – A Literature Review

    by Adam Jan Ząbek, Jakub Paweł Kuźniar, Emilia Gabriela Chrzanowska, Michalina Zagalska, Marta Turek, Tomasz Tamborski, Adam Grzebinoga, Julia Szlążek, Iwona Pudełko, Barbara Roguska

    Hydroxychloroquine (HCQ) is a long-established drug, initially used to treat malaria and later widely applied in autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). As an immunomodulatory agent, HCQ plays a crucial role in managing chronic inflammation. Despite its benefits, its use requires monitoring due to potential adverse effects, including retinopathy and myopathy.[1] Objective This review analyzes HCQ’s role in modern medicine and public health, particularly in treating autoimmune diseases. It also examines controversies surrounding its use during the COVID-19 pandemic and its implications for medical education and health prevention. Current Knowledge HCQ modulates immune responses and lysosomal function, making it effective in controlling inflammation. Although hypotheses suggested antiviral properties against SARS-CoV-2, clinical trials did not confirm its efficacy, leading to changes in treatment recommendations. Methods A literature review of 32 scientific articles was conducted using PubMed and Google Scholar, focusing on HCQ’s history, mechanism of action, and applications in medicine, public health, and education. Conclusion HCQ remains a key treatment for autoimmune diseases, though its long-term safety is still under study. Continuous research and medical education are essential for optimizing its use, including potential applications in sports and rehabilitation, where chronic inflammation affects recovery and performance.